著者

本田 義輝 中野 眞汎

出版者

一般社団法人 日本医療薬学会

雑誌

病院薬学 (ISSN:03899098)

巻号頁・発行日

vol.23, no.3, pp.219-224, 1997-06-10 (Released:2011-08-11)

参考文献数

7

被引用文献数

8 11

---

The adsorption characteristics of various adsorbates by spherical charcoal (Kremezin ®) were studied in vitro and then compared with those of powdered medical charcoal. Medical charcoal adsorbs substances with molecular weights ranging from several hundred daltons to several thousand daltons. Kremezin, however, adsorbs only low molecular weight substances with molecular weights of up to several hundred daltons. Therefore, the adsorption selectivity of Kremezin, which is related to the molecular weight of adsorbate, seemed to contribute to the specific pharmacological action of this drug under clinical conditions. In batch adsorption tests for various amines, amino acids and organic acids with molecular weightsof from 45 to 251, both adsorbents showed similar behaviors. An increase in the size of the adsorbate molecule enhanced the degree of adsorption, especially in compounds that are analogs. The molecular structure also seemed to be an important factor in the adsorption phenomena; an aromatic ring tended to increase the adsobability while the amino group, carboxyl group and hydroxyl group all showed a decrease in adsorbability.

著者

本田 義輝 中野 尚美 中野 眞汎

出版者

公益社団法人 日本薬学会

雑誌

ファルマシア (ISSN:00148601)

巻号頁・発行日

vol.21, no.5, pp.414-417, 1985-05-01 (Released:2018-08-26)

著者

本田 義輝 中野 眞汎

出版者

日本病院薬剤師会

雑誌

病院薬学

巻号頁・発行日

vol.20, no.4, pp.265-272, 1994

被引用文献数

4

---

Adsorption characteristics of creatinine by activated carbon beads consisting of about 67% activated carbon powder in ager were studied in vitro and compared with those of Kremezin^<[◯!R]> from the standpoint of usefulness for sequestering uremic wastes and uremic toxins exsorbed into the intestine. The extent and rate of creatinine adsorption on carbon in the beads were almost equal to those of the naked powder, and the preparation also demonstrated a similar adsorption behavior for creatinine as compared with Kremezin under the conditions of the presence of various ionic and nonionic additives. Furthermore, uremic peaks 2a and 2b on HPLC specific to chronic renal failure were readiy eliminated by the treatment of the beads in the uremic plasma. On the other hand, although the adsorption capacities of Kremezin for drugs were generally equal to those of medical carbon, the adsorption rate by Kremezin was smaller, but inferiority was not so serious as to make Kremezin useless as an oral antidote in acute intoxications brought on by drugs.

著者

田上 直美 高野 佐知子 本田 義輝 〓田 聡 谷崎 正典 吉原 博幸 中野 眞汎

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.28, no.6, pp.583-589, 2002-12-10 (Released:2011-03-04)

参考文献数

5

被引用文献数

4 2

---

Recently, pharmaceutical care is increasing in importance. Pharmacists must provide pharmaceutical counseling services that can satisfy all patients. However, there are limitations in manpower and a lot of effort has to put devoted to using such manpower as effectively as possible. With this in mind, we developed a medication consultation support system for pharmacists to achieve an improved medical quality. As a result, labor saving results were obtained in document preparation of medication histories, laboratory test histories, and medication instruction records. Furthermore, the total work need to create medication instruction daily reports, monthly reports, etc. also decreased. As a result, the time and work pressure experienced by pharmacists decreased while the overall quality of this system was maintained.

著者

本田 義輝 齋藤 秀之

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.31, no.5, pp.391-398, 2005-05-10 (Released:2011-03-04)

参考文献数

15

被引用文献数

9 11

---

Very little quality information is available for generic pharmaceutical preparations and this is particularly so for injectable preparations for which few quality studies have been conducted. With this in mind, we conducted an inter-lot quality variation investigation on nafamostat mesilate preparations for both the original and generic products and compared the results. The investigation involved measuring amounts of impurities other than those of the active ingredient by high performance liquid chromatography.For the nine generic products investigated, impurity amounts were about 2.4 times that of the original (min. 2.0 times-max. 3.1 times). We determined that these differences were not due to hydrolysates of the active ingredient but to unknown substances since the amounts of these unknown substances in the generic products were about 5.7 times (min. 4.7 times-max. 8.0 times) their amount in the original product.Concerning inter-lot variation (maximum value-minimum value), we found that the variation in total impurity amounts for the generic products was 1.8 times (min. 0.7 times-max. 2.8 times) that of the original product, while the variation in unknown substance amounts for the generics was 3.1 times (min. 1.0 times-max.4.6 times) that for the original.The results of the present study suggest that it is necessary to take inter-lot variation into account in evaluating the quality of generic products. They also suggest that the higher contents of unknown impurities in the generics could be a cause of the in-circuit precipitation which has been reported with generic versions of nafamostat mesilate during blood purification in the clinical setting.

著者

本田 義輝 齋藤 秀之

出版者

日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.31, no.5, pp.391-398, 2005-05-10

参考文献数

15

被引用文献数

8 11

---

Very little quality information is available for generic pharmaceutical preparations and this is particularly so for injectable preparations for which few quality studies have been conducted. With this in mind, we conducted an inter-lot quality variation investigation on nafamostat mesilate preparations for both the original and generic products and compared the results. The investigation involved measuring amounts of impurities other than those of the active ingredient by high performance liquid chromatography. For the nine generic products investigated, impurity amounts were about 2.4 times that of the original (min. 2.0 times-max. 3.1 times). We determined that these differences were not due to hydrolysates of the active ingredient but to unknown substances since the amounts of these unknown substances in the generic products were about 5.7 times (min. 4.7 times-max. 8.0 times) their amount in the original product. Concerning inter-lot variation (maximum value-minimum value), we found that the variation in total impurity amounts for the generic products was 1.8 times (min. 0.7 times-max. 2.8 times) that of the original product, while the variation in unknown substance amounts for the generics was 3.1 times (min. 1.0 times-max. 4.6 times) that for the original. The results of the present study suggest that it is necessary to take inter-lot variation into account in evaluating the quality of generic products. They also suggest that the higher contents of unknown impurities in the generics could be a cause of the in-circuit precipitation which has been reported with generic versions of nafamostat mesilate during blood purification in the clinical setting.